| EN

The Formation of New Board (2020 - 2022)

The Hong Kong Association of The Pharmaceutical Industry (HKAPI) held its Annual General Meeting on 2 April 2020 and delighted to announce the formation of the New Board (2020 – 2022) with the following members:


General Manager
Roche Hong Kong Limited


Vice President

Ms. Dorine LEUNG
General Manager & Country Vice President
Novartis Pharmaceuticals (HK) Ltd.

Board of Directors (by alphabetical order of their surname)


General Manager, Hong Kong & Macau
Amgen Hong Kong Limited


Mr FONG Wai-ting

Head of Country Management & Vice President, Healthcare
Medinova AG


Ms Peggy FUNG

General Manager, Pharmaceuticals – Hong Kong & Macau
GlaxoSmithKline Ltd.



Mr Alex HO

General Manager
Janssen, Johnson & Johnson (HK) Limited


Mr Gwenaël MENEUX

General Manager, Hong Kong & Macau
AstraZeneca Hong Kong Limited


Mr Richard SUN

General Manager, HK, Malaysia & Singapore
AbbVie Limited


Mr Lawrence WONG

General Manager, Hong Kong
Ferring Pharmaceuticals Limited



While congratulating the new Board members on board, we also thank those Board members who served in 2018 -2020 for their remarkable leadership, time and effort for serving the industry.

In addition, we shall thank all taskforce leads and task force members for their valuable contribution and passion to work for the strategic initiatives and for the system betterment in the past two years.

With that collective wisdom and effort, the HKAPI is able to continue bringing visible achievements in driving expedient access to innovative healthcare solutions for the people of Hong Kong and Macao with high ethical standard.

Close Bitnami banner